News

Produodopa available to treat advanced Parkinson’s in Scotland

Produodopa (foslevodopa/foscarbidopa; also known as ABBV-951), a continuous infusion formulation of levodopa/carbidopa, will be available to advanced Parkinson’s disease patients in Scotland whose severe motor fluctuations and involuntary movements are no longer controlled by those standard therapies. The Scottish Medicines Consortium (SMC) restricted use of AbbVie’s subcutaneous…

AI uses gene activity patterns to ID Parkinson’s disease pathways

An artificial intelligence (AI)-based software called NetraAI was able to separate subgroups of Parkinson’s disease patients based on their gene activity patterns, helping to better understand the complex pathways that contribute to the neurodegenerative disease. Through the analysis, scientists identified immune signaling as an important disease-related process. The function…

Investigational Parkinson’s therapy ALX-001 advances to Phase 2 trial

Allyx Therapeutics will advance into Phase 2 clinical development of ALX-001, its investigational therapy for neurodegenerative conditions, in people with Parkinson’s disease. The company announced the move alongside the presentation of positive data from a Phase 1b study (NCT05804383) at the International Conference on Alzheimer’s and…

Fosgonimeton shows potential as dementia treatment, Athira says

Athira Pharma’s fosgonimeton (ATH-1017) shows promise as a therapy for neurodegenerative conditions including Parkinson’s disease, according to data presented at the recent International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2024), in Portugal. The investigational small molecule demonstrated “encouraging pro-cognitive effects” in the exploratory…

NT-0796 shows sustained easing of inflammation in Phase 1/2 trial

NodThera’s potential oral therapy for Parkinson’s disease, NT-0796, continues to show promise in countering damaging inflammation in treated patients, according to new findings from a Phase 1b/2a clinical trial. Treatment with NT-0796 for 28 days safely reduced pro-inflammatory markers in the patients’ cerebrospinal fluid (CSF, the liquid surrounding…